An internationally recognized leader in molecular pharmacology and neurobiology, Dr. Bohn recently joined USF Health. She is ...

Researchers have used large-scale virtual compound libraries, in silico screening and computer simulations to identify small ...

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic ...

Researchers at Karolinska Institutet have identified small molecules capable of influencing a hard-to-target receptor family ...

Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...

Preclinical studies of the serotonin 2A (5-HT2A) antagonist deramciclane suggested an anxiolytic profile, which has not been unequivocally established in the clinic. The same receptor profile also ...